Annual Meeting

MCP to host immunopeptidomics session

Pierre Thibault
By Pierre Thibault
Feb. 11, 2022

The editorial leadership team of the journal Molecular & Cellular Proteomics has chosen four investigators to present their current research during a symposium at the 2022 American Society for Biochemistry and Molecular Biology Annual Meeting in Philadelphia.

Al Burlingame, MCP editor-in-chief, said, “This symposium will feature remarkable scientists who through their investigations have leveraged tools in immunology and molecular proteomics to uncover tumor antigens for the development of cancer vaccines.”

The session, titled “Exciting Biological Insights Revealed by Proteomics,” will be held at 3:15 p.m., Monday, April 4 in room 126A.

I will be chairing the session as well as giving a talk. I am a professor and principal investigator at the Institute for Research in Immunology and Cancer of Université de Montréal. My group employs mass spectrometry and proteogenomic approaches to identify tumor-specific antigens and to gain biological insights into their biogenesis.

I look forward to sharing the session with these three researchers:

Michal Bassani–Sternberg is an assistant professor at the department of oncology at the University of Lausanne. By leveraging high-sensitivity mass spectrometry, her group identifies clinically relevant cancer-specific major histocompatibility complex I ligands for personalized cancer immunotherapy.

Victor H. Engelhard is a professor of microbiology, immunology and cancer biology at the University of Virginia. His group made seminal contributions to the further understanding of immune responses to tumors and the identification of major histocompatibility complex–restricted tumor antigens.

Susan Klaeger is a research scientist in the proteomics platform at the Broad Institute of the Massachusetts Institute of Technology and Harvard University. Her work focuses on the application of proteomics to translational research and on the development of methods to study antigen presentation and prediction algorithms for human leukocyte antigen binding.

Read more about these speakers and their research in the following pages.

Bringing immunopeptidomics to the bedside
Michal Bassani–Sternberg

It’s what’s on the outside that counts
Victor H. Engelhard

Improving disease detection for personalized vaccines
Susan Klaeger

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Pierre Thibault
Pierre Thibault

Pierre Thibault is a professor and principal investigator at the Institute for Research in Immunology and Cancer of Université de Montréal.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in People

People highlights or most popular articles

Garcia–Blanco, Li elected to VASEM
Member News

Garcia–Blanco, Li elected to VASEM

April 6, 2026

They are two of 22 Virginia-based scientists honored for their leadership in science, engineering and medicine.

Huttenhain, Peng win HUPO awards
Member News

Huttenhain, Peng win HUPO awards

March 30, 2026

Huttenhain and Peng received the Distinguished Service Award and Clinical and Translational Proteomics Award, respectively.

Introducing STEM before self-doubt
Profile

Introducing STEM before self-doubt

March 26, 2026

With hair biology workshops and hands-on STEM programs, Shyretha Brown is building pathways for young girls to see themselves in science. Through Building Bridges, she blends education, identity and access to expand who feels welcome in STEM.

In memoriam: Richard Wolfenden
In Memoriam

In memoriam: Richard Wolfenden

March 23, 2026

He was an enzymologist whose work helped spur the development of ACE inhibitor drugs and has been an ASBMB member since 1967.

Tansey named department chair
Member News

Tansey named department chair

March 16, 2026

He has been a faculty member at Otterbein University since 2002.

In memoriam: Joel Habener
In Memoriam

In memoriam: Joel Habener

March 16, 2026

He discovered GLP-1, which helped pave the way for transformative diabetes and obesity therapies, and he was an ASBMB member for 25 years.